In 2015 there was a public outcry over the price increase in Daraprim (pyrimethamine) by Turing Pharmaceuticals AG (Turing). Daraprim was a drug that was widely used by a small population of U.S. patients to treat toxoplasmosis. Soon after Turing acquired its commercialization rights in August 2015, the company increased the list price of the drug by over 5,000 per cent. The increase led to consumer protests in the United States, and the media vehemently condemned Turing's action of raising the price for the decades-old drug that had gone off-patent in 1970. Later, the U.S. Congress stepped in, demanding that Turing's officials clarify how they could justify the high price of Daraprim. How should Turing respond to the public outcry? Should Turing stand by the increased price for Daraprim? How could it handle the outcry from the patient groups that needed Daraprim? Shernaz Bodhanwala is affiliated with FLAME University.

【書誌情報】

ページ数：9ページ

サイズ：A4

商品番号：HBSP-W17678

発行日：2017/11/8

登録日：2018/1/15